Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK
The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.
Related Articles
RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up
For every 100,000 runners who complete the full 42.2 km distance, there will be one cardiac arrest, new data show.
Funding for Women’s Health Initiative Imperiled, But Appears Secure for Now
Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha Gulati.
TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms
It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?
Pairing CIED Lead Extraction With Tricuspid Interventions Appears Safe
Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.
GLP-1 Drugs May Have Role in Secondary Prevention of AF
The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.
Beyond the Data: The ALIGN-AR Trial
Mamas Mamas sits down with Raj Makkar to discuss new data on the treatment of aortic regurgitation.
Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds
SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.
Funding for Women’s Health Initiative Imperiled, But Appears Secure for Now
Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha Gulati.
Plant-Derived Compound Shows Early Promise for Small AAAs
In aneurysms normally chosen for surveillance, the endovascular technique slowed growth by 70% in the small phase I trial.